Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it has submitted a Biologics ...
Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemot ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
AbbVie said on Monday it would partner with Chinese drug developer RemeGen for an experimental treatment targeting solid ...
Phanes Therapeutics reports positive phase 2 results of spevatamig in combo with chemotherapy in frontline treatment of metastatic PDAC: San Diego Monday, January 12, 2026, 18:00 ...
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...
Driven by a paradigm shift to curative early-stage interventions and surging ADC demand, the market offers massive upside.
AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- via IBN - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback